Delivery Order SPE2DB20D3103-SPE2DB25FP0Q1
Award Date 6/5/25
Potential Completion Date 6/6/25
Potential Value $9.5K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency (DLA) awarded a Delivery Order valued at $11,981.16 to AmerisourceBergen Drug Corp for the supply of Kanjinti 420 mg vials. This is a firm fixed-price, competitively awarded contract with no set-aside designation, with an ultimate completion date of November 14, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor and will perform the work at its corporate office location. Kanjinti is a biosimilar medication...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp's Corporate Office Division, a major pharmaceutical distributor, for the supply of KANJINTI 420 MG VIALS. The firm-fixed-price contract has a ceiling value of $14,564.76 and a completion date of May 10, 2024. AmerisourceBergen, a subsidiary of Cencora, Inc., holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical worth up to $999,999,999.00 through December 2025,...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corporation's Corporate Office Division. The contract is for the supply of 4,565,402,851 units of the pharmaceutical product KANJINTI 420 MG VIALS. The contract is a firm-fixed price award with a ceiling value of $14,730.10 and an ultimate completion date of August 12, 2024. Amerisourcebergen, a major pharmaceutical distributor, has been awarded this contract to...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 22, 2025, for the supply of Ontruzant 150 mg vials, a biosimilar oncology medication, with a ceiling value of $2,305.20. This competitively awarded, firm fixed-price delivery order is scheduled for completion by October 23, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The award utilized no set-aside designation, reflecting open competition for this medical...
- The Department of Defense Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for 150 mg vials of Ontruzant, a biosimilar medication, valued at $7,045.40. This contract was competitively awarded without a set-aside designation on September 8, 2025, with an ultimate completion date of September 9, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The U.S. Defense Department's Medical Supply Chain awarded a $11,764.70 delivery order to AmerisourceBergen Drug Corp on October 16, 2025, for the supply of Ontruzant 150 mg vials. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of October 17, 2025, and carries no set-aside designation, indicating it was competitively awarded. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) for 420 mg vials of Trazimera, a trastuzumab biosimilar used in cancer treatment, with a ceiling value of $7,968.07. The award, made on October 31, 2025, with an ultimate completion date of November 3, 2025, represents a firm fixed-price delivery order with no set-aside designation. The pharmaceutical product will be supplied to the place of performance in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a $21,363.36 delivery order to AmerisourceBergen Drug Corp for 150 mg Herceptin vials, with a completion date of September 30, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is performed at the contractor's facility in Conshohocken, Pennsylvania. Herceptin (trastuzumab) is a monoclonal antibody used in cancer treatment, particularly for HER2-positive breast cancer cases, making this a critical pharmaceutical supply...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 24, 2025, for the supply of Ontruzant 420 mg vials, a biosimilar medication used in cancer treatment. This competitively awarded, non-set-aside contract carries a ceiling value of $18,701.64 and is structured as a firm fixed-price delivery order with an ultimate completion date of April 25, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the...
- The Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 29, 2025, for the supply of Ontruzant 150 mg vials with a ceiling value of $9,459.31. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was competitively procured. The order is scheduled for ultimate completion by September 30, 2025, and will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. This...